ARTIRIA Medical raises CHF 3 million to improve stroke treatments

Please login or
register
15.07.2020
Brain

Less than one year since its foundation, ARTIRIA Medical, a neurovascular start-up aiming to improve stroke treatments, has closed a CHF 3M Series A financing led by 4FO Venture Partners. The funds will enable the company to bring its first product through clinical validation and regulatory approval.

Every year, 13 million people suffer a stroke which often results in severe disabilities and death. Currently, the standard of care is based on a minimally invasive approach, using the patient’s arteries as an access route to reach the brain smoothly in order to deliver life-saving treatments locally. However, this procedure can be very challenging, as the device navigation takes place in a dense network of tiny brain arteries. This complexity causes surgeons to lose significant and critical time before they can effectively deliver the therapy.

ARTIRIA Medical, an EPFL Spin-off founded in August 2019 by Guillaume Petit- Pierre and Marc Boers, developed a guidewire based on its cutting-edge technology that facilitates micromotion deep in the brain arteries, thus enabling seamless navigation towards a cerebral lesion and better stroke treatment. “The company’s clinical goal is to ease the procedure and reduce the duration of stroke treatment, therefore improving patient outcome”, explains Guillaume Petit-Pierre, Founder and CEO of ARTIRIA.

Thanks to the capital increase of CHF 3 million, the start-up will now proceed to the next stanges which focuses on accelerating the clinical and regulatory development of its patented micro-actuated device which has the potential to improve stroke treatment significantly. The investment round, led by 4FO Venture Partners, was joined by investiere, the Zürcher Kantonal Bank (ZKB), NEST pension fund, Venture Kick and business angels.

Together with this financing round, the company also announces the appointment of Jacques Essinger (former CEO of Symetis), Jean-Pierre Rosat (General Partner of 4FO Venture) and Didier Cowling (former CEO of Kuros Biosciences) to the Board of Directors.

“We are pleased to have investors sharing our vision and a board of directors with significant medical device expertise to help us delivering it,” says Marc Boers, Founder and COO of ARTIRIA.

0Comments

More news about

Artiria Medical SA

Company profiles on startup.ch

Artiria Medical SA

rss